Modified GRF(1-29), commonly sold as CJC-1295 No DAC, is a short-acting GHRH analog used to study pituitary GH release and downstream IGF-1 signaling. Its key feature is improved peptide stability without the long albumin-binding exposure produced by DAC.

What this formula features: A stabilized 29-residue GHRH scaffold that keeps the research focus on pulse-like GH release rather than multi-day exposure. Direct controlled human data for the no-DAC variant are limited, so its expected behavior is largely inferred from GHRH(1-29) pharmacology and the better-characterized DAC form.

Typical research readouts: Common endpoints are GH release or pulse amplitude, GH area-under-the-curve, downstream IGF-1, pituitary GHRH-receptor signaling, and time-course comparisons versus native GHRH or DAC-CJC controls. The short-acting profile is a key experimental distinction.

This product is strictly for research purposes only. Not approved for human or animal use.